Catabasis Pharmaceuticals' drug for the rare disease Duchenne...

Catabasis Pharmaceuticals' drug for the rare disease Duchenne muscular dystrophy (DMD) missed its primary endpoint in the second portion of a mid-stage study, according to top-line results the company released Tuesday.Part B of the three-part MoveDMD study enrolled 31 boys ages four to seven with DMD who were then given either one of two doses of the drug in question, edasalonexent, or a placebo over a 12-week period. Results showed that while the drug had a solid safety profile, it did not lead to significantly improved muscle composition or reduced inflammation — the primary endpoints of the study.Catabasis said it will continue with Part C of the study, an open-label expansion test, with interim results expected during the second quarter and fuller readouts later this year.